Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.65 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.62 |
| ▸ | MAOA | P21397 | 2/20 | 0.59 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.59 |
| ▸ | BCHE | P06276 | 1/20 | 0.59 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28311147 | 0.92 | NR4A2 (0.62) | MAOBNR4A2MAOACYP4F2CYP4A11 | |
| Isothiocyanate SCHEMBL28295717 | 0.90 | MAOB (0.55) | MAOBNR4A2MAOACYP4F2CYP4A11 | |
| SCHEMBL26830356 | 0.90 | MAOB (0.58) | MAOBNR4A2MAOACYP4F2CYP4A11 | |
| SCHEMBL11959694 | 0.89 | MAOB (0.72) | MAOBNR4A2MAOA | |
| SCHEMBL1268719 | 0.86 | MAOB (0.81) | MAOBNR4A2MAOACYP4F2CYP4A11 | |
| SCHEMBL7817242 | 0.85 | MAOB (0.54) | MAOBNR4A2MAOACYP4F2CYP4A11 | |
| SCHEMBL995120 | 0.85 | MAOB (0.73) | MAOBNR4A2MAOA | |
| SCHEMBL5042093 | 0.84 | ALOX5 (0.55) | MAOBMAOACYP4F2CYP4A11BCHE | |
| SCHEMBL31160636 | 0.84 | MEN1 (0.59) | MAOBMAOACYP4F2CYP4A11BCHE | |
| SCHEMBL8033064 | 0.84 | MAOB (0.68) | MAOBNR4A2MAOAMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024005460-A1 | COMPOUND COMPRISING SELF-IMMOLATIVE GROUP AND LIGAND-DRUG CONJUGATE COMPRISING SAME | 주식회사 트리오어 | 2024-01-04 | — | — | WO | disclosed |
| US-11664093-B2 | Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-05-30 | — | — | US | disclosed |
| CN-109195608-A | Boron-containing small molecules | 比尔及梅琳达盖茨基金会 | 2019-01-11 | — | — | CN | disclosed |
| US-20140018538-A1 | HIGH-VALENT PALLADIUM FLUORIDE COMPLEXES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018538-A1 | HIGH-VALENT PALLADIUM FLUORIDE COMPLEXES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018538-A1 | HIGH-VALENT PALLADIUM FLUORIDE COMPLEXES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-01-16 | — | — | US | disclosed |
| EP-2606056-A2 | HIGH-VALENT PALLADIUM FLUORIDE COMPLEXES AND USES THEREOF | President and Fellows of Harvard College (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024604-A2 | HIGH-VALENT PALLADIUM FLUORIDE COMPLEXES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024604-A2 | HIGH-VALENT PALLADIUM FLUORIDE COMPLEXES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-02-23 | — | — | WO | disclosed |
| US-7906556-B2 | Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| EP-1537091-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| US-6809110-B2 | NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID | HOFFMANN-LA ROCHE INC. | 2004-10-26 | — | — | US | disclosed |
| US-20040116487-A1 | Novel oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040110807-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2004031162-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004020420-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-03-11 | — | — | WO | disclosed |
| US-6218431-B1 | GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES | BAYER CORPORATION | 2001-04-17 | — | — | US | disclosed |
| CN-1239474-A | Substituted pyridines and biphenyls as antihypercholesterolemic, antihyperlipidemic and antihyperglycemic agents | BAYER AG (US) | 1999-12-22 | — | — | CN | disclosed |
| EP-0934274-A1 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | Bayer Corporation (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998004528-A2 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | BAYER CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018538-A1 | HIGH-VALENT PALLADIUM FLUORIDE COMPLEXES AND USES THEREOF | NECTIN4, FIS1, DNM1 | MAOB 1977/4885NR4A2 3024/4885MAOA 1788/4885 |
| US-20040110807-A1 | Thiazole derivatives | SLC5A1, GPR119, INSR | MAOB 4027/4885NR4A2 430/4885MAOA 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.